Baxter International | BAX - Les Charges D'Exploitation





Les Charges D'Exploitation Changement Date
Abbott USD 9.31B 104M 2026-03
AngioDynamics USD 81.95M 1.68M 2025-09
Artivion USD 111.2M 9.45M 2025-12
AtriCure USD 140.72M 2.71M 2026-03
Avanos Medical USD 782.1M 625.97M 2026-03
Baxter International USD 6.04B 2.85B 2026-03
Becton, Dickinson and Co. USD 24.13B 19.54B 2026-03
Boston Scientific USD 4.15B 107M 2026-03
Cooper Companies USD 1.11B 301.2M 2026-03
Dexcom USD 936.6M 0 2026-03
Edwards Lifesciences USD 1.13B 65.4M 2026-03
Fresenius EUR 5.25B 337M 2025-12
Globus Medical USD 595.85M 49.26M 2026-03
Halozyme Therapeutics USD 192.19M 18.88M 2026-03
ICU Medical USD 514.62M 4.48M 2025-12
Inogen USD 49.14M 665K 2024-09
Insulet USD 639.7M 2.2M 2026-03
Integra LifeSciences USD 1.04B 673.49M 2026-03
Intuitive Surgical USD 1.91B 89.8M 2026-03
J&J USD 17.44B 1.53B 2026-03
Laboratory Of America USD 3.13B 6.3M 2026-03
Masimo USD 326.2M 2.4M 2026-03
Medtronic USD 7.72B 436M 2026-03
Merit Medical Systems USD 337.72M 2.02M 2026-03
Quest Diagnostics USD 2.5B 76M 2026-03
Smith & Nephew USD 2.52B 84M 2025-12
Stryker USD 4.92B 284M 2026-03
Tandem Diabetes Care USD 282.09M 9.97M 2025-12
Teleflex USD 3.08B 2.55B 2026-03
Terumo JPY 268.87B 16.12B 2026-03
Zimmer Biomet Holdings USD 1.69B 249.3M 2026-03